

Michael A. Rogawski, M.D., Ph.D.

Philosophy of Care	Dr. Rogawski is a careful listener who selects from a broad range of therapies to tailor a treatment regimen to the patient's unique needs, with the goals of an improved quality of life and meeting individual health objectives.
Clinical Interests	Dr. Rogawski is a neurologist offering care for headache and epilepsy.
Title	Professor, Department of Neurology
Specialty	Neurology
Department	Neurology
Division	Neurology
Clinic	UC Davis Medical Group, Sacramento - Midtown
Center/Program Affiliation	Center for Neuroscience
Address/Phone	UC Davis Midtown Ambulatory Care Center, Midtown Neurology Clinic, 3160 Folsom Blvd Suite 2100 Sacramento, CA 95816 **Phone:** 916-734-3588
Additional Phone	Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Email	rogawski@ucdavis.edu
Education	M.D., Yale University School of Medicine, New Haven CT 1980 Ph.D., Pharmacology, Yale University, New Haven CT 1980 B.A., Biophysics, Amherst College, Amherst MA 1974
Internships	Internal Medicine, Yale University School of Medicine, Waterbury Hospital, Waterbury CT 1980-1981
Residency	Neurology, Johns Hopkins Hospital, Baltimore MD 1982-1985
Fellowships	Neurology, Johns Hopkins Hospital, Baltimore MD 1982-1985 Neurology, National Institute of Health, Bethesda MD 1986-1989
Board Certifications	Certificate of Added Qualification - Headache Medicine
Professional Memberships	American Academy of Neurology

UCDAVIS HEALTH



Michael A. Rogawski, M.D., Ph.D.

American Epilepsy Society, Fellow
American Headache Society
American Neurological Association, Fellow
National Headache Foundation
Society for Neuroscience

Honors and Awards

Designated Honorary Title of Distinguished Professor, 2021
Elected Fellow, National Academy of Inventors, 2020
Innovator of the Year, UC Davis Chancellor's Innovation Awards, 2019
Elected Fellow, American Association for the Advancement of Science (Section on Neuroscience), 2018
Neuroendocrine Research Award, American Academy of Neurology, 2015

Select Recent Publications

Rogawski MA, Slatko G. A randomized, open-label, two-treatment crossover study to evaluate the effect of food on the pharmacokinetics of diazepam nasal spray in healthy adults. Epilepsia. 2022 Nov 22. doi:10.1111/epi.17459. Epub ahead of print. PMID:36413125.

Vuu I, Patterson EE, Wu CY, Zolkowska D, Leppik IE, Rogawski MA, Worrell GA, Kremen V, Cloyd JC, Coles LD. Intravenous and Intramuscular Allopregnanolone for Early Treatment of Status Epilepticus: Pharmacokinetics, Pharmacodynamics, and Safety in Dogs. J Pharmacol Exp Ther. 2022 Feb;380(2):104-113. doi:10.1124/jpet.121.000736. Epub 2021 Dec 3. PMID: 34862270.

Oskarsson B, Mauricio EA, Shah JS, Li Z, Rogawski MA. Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis. Muscle Nerve. 2021 Aug;64(2):215-219. doi:10.1002/mus.27328. Epub 2021 May 27. PMID:34008857.

Zolkowska D, Dhir A, Rogawski MA. Perampanel, a potent AMPA receptor antagonist, protects against tetramethylenedisulfotetramine-induced seizures and lethality in mice: comparison with diazepam. Arch Toxicol. 2021 Jul;95(7):2459-2468. doi:10.1007/s00204-021-03053-9. Epub 2021 Apr 29. PMID:33914090.

UCDAVIS HEALTH



Michael A. Rogawski, M.D., Ph.D.

Zolkowska D, Wu CY, Rogawski MA. Intranasal Allopregnanolone Confers Rapid Seizure Protection: Evidence for Direct Nose-to-Brain Delivery. Neurotherapeutics. 2021 Jan;18(1):544-555. doi:10.1007/s13311-020-00985-5. Epub 2021 Jan 6. PMID:33405197.

Hernandez GD, Solinsky CM, Mack WJ, Kono N, Rodgers KE, Wu CY, Mollo AR, Lopez CM, Pawluczyk S, Bauer G, Matthews D, Shi Y, Law M, Rogawski MA, Schneider LS, Brinton RD. Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimers Dement (N Y). 2020 Dec 16;6(1):e12107. doi:10.1002/trc2.12107. PMID:33344752.

Dhir A, Bruun DA, Guignet M, Tsai YH, González E, Calsbeek J, Vu J, Saito N, Tancredi DJ, Harvey DJ, Lein PJ, Rogawski MA. Allopregnanolone and perampanel as adjuncts to midazolam for treating diisopropylfluorophosphate-induced status epilepticus in rats. Ann N Y Acad Sci. 2020 Nov;1480(1):183-206. doi:10.1111/nyas.14479. Epub 2020 Sep 11. PMID:32915470.

Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15;168:107966. doi:10.1016/j.neuropharm.2020.107966. Epub 2020 Jan 14. PMID:32120063.

Rogawski MA. Antiseizure Drugs. Katzung BG, Vanderah TW (eds). Basic and Clinical Pharmacology, 15th Edition, McGraw-Hill Education, 2021;24:422-455.

Some publications are available at the following link:

© 2024 UC Regents

UCDAVIS HEALTH